Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE trial of secukinumab in adults with moderate to severe hidradenitis suppurativa
MOH_2019-01-15_004862Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (4 arms), sponsored by Novartis. Primary endpoint: HiSCR response rate at week 16 versus placebo. Started Dec 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2019-01-15_004862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-15_004862.